Cargando…

Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C

BACKGROUND AND AIM: The accuracy for predicting virological outcomes of peginterferon-α and ribavirin therapy in patients with chronic hepatitis C is limited to approximately 80%, even with IL28B genotyping. Our in vitro study revealed that the numbers of (TA) dinucleotide repeats [(TA)n] of rs72258...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masaki, Naohiko, Sugiyama, Masaya, Shimada, Noritomo, Tanaka, Yasuhito, Nakamuta, Makoto, Izumi, Namiki, Watanabe, Sumio, Tsubota, Akihito, Komatsu, Masafumi, Masaki, Tsutomu, Enomoto, Nobuyuki, Yoneda, Masashi, Murata, Kazumoto, Ito, Kiyoaki, Koike, Kazuhiko, Mizokami, Masashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Clinical Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263356/ https://www.ncbi.nlm.nih.gov/pubmed/24910341 http://dx.doi.org/10.1111/jgh.12646

Ejemplares similares

Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection
por: Murata, Kazumoto, et al.
Publicado: (2018)

Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients
por: Murata, Kazumoto, et al.
Publicado: (2013)

Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene
por: Watanabe, Tsunamasa, et al.
Publicado: (2013)

Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study
por: Ide, Kazuki, et al.
Publicado: (2016)

Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin
por: Kim, Kyung-Ah
Publicado: (2011)

Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin
por: Toyoda, Hidenori, et al.
Publicado: (2012)

In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome
por: Todt, Daniel, et al.
Publicado: (2016)

Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study
por: Masaki, Naohiko, et al.
Publicado: (2015)

Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues
por: Fan, Rong, et al.
Publicado: (2016)

Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis
por: Zhang, Bing, et al.
Publicado: (2015)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
por: Shiha, Gamal, et al.
Publicado: (2019)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study
por: Hayashi, Norio, et al.
Publicado: (2014)

Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study
por: Kimura, Masamichi, et al.
Publicado: (2022)

Identification of circulating microRNAs as potential biomarkers for hepatic necroinflammation in patients with autoimmune hepatitis
por: Saeki, Chisato, et al.
Publicado: (2022)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database
por: Sato, Izumi, et al.
Publicado: (2014)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
por: Manfredi, Roberto, et al.
Publicado: (2010)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
por: Jung, Young Kul, et al.
Publicado: (2013)

Does long-term use of proton pump inhibitors cause hypomagnesaemia in Japanese outpatients?
por: Takeda, Yasuhito, et al.
Publicado: (2015)

Peginterferon Alfa-2a plus Ribavirin in Japanese Patients Infected with Hepatitis C Virus Genotype 2 Who Failed Previous Interferon Therapy
por: Kanda, Tatsuo, et al.
Publicado: (2012)

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients
por: Watanabe, Takao, et al.
Publicado: (2016)

Loss of organic anion transporting polypeptide 1B3 function causes marked delay in indocyanine green clearance without any clinical symptoms
por: Kagawa, Tatehiro, et al.
Publicado: (2017)

Enterococcus casseliflavus KB1733 Isolated from a Traditional Japanese Pickle Induces Interferon-Lambda Production in Human Intestinal Epithelial Cells
por: Satomi, Shohei, et al.
Publicado: (2022)

A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection
por: Xiao, Nan, et al.
Publicado: (2010)

Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study
por: Hayashi, Norio, et al.
Publicado: (2015)

Serum Lipoprotein Profiles and Response to Pegylated Interferon Plus Ribavirin Combination Therapy in Patients With Chronic HCV Genotype 1b Infection
por: Aizawa, Yoshio, et al.
Publicado: (2013)

Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy
por: Kadokura, Makoto, et al.
Publicado: (2011)

Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals
por: Izumi, Namiki, et al.
Publicado: (2018)

miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis
por: Van Renne, Nicolaas, et al.
Publicado: (2018)

Effect of physical exercise on sarcopaenia in patients with overt hepatic encephalopathy: a study protocol for a randomised controlled trial
por: Yoh, Kazunori, et al.
Publicado: (2017)

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis
por: Kim, Kyung Hoon, et al.
Publicado: (2011)

Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin
por: Yu, Ming-Lung, et al.
Publicado: (2012)

Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis
por: Peng, Qin, et al.
Publicado: (2016)

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection
por: Janssen, Harry L A, et al.
Publicado: (2023)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
por: Flisiak, Robert, et al.
Publicado: (2016)

Sarcoidosis with Both Plaques and Subcutaneous Nodules Associated with Combination Therapy with Peginterferon α-2a and Ribavirin
por: Kondo, M., et al.
Publicado: (2011)

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
por: Jeong, Seok Hoo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_177lhalornknt50i2c05u0i370